ArticleNaunyn-Schmiedeberg's archives of pharmacology2026
Integrating UHPLC-MS, Network Pharmacology, and Molecular Docking techniques to explore the neuroprotective effect of Mirificin.
Article in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ischemic stroke (IS) is a complex cerebrovascular disease with a high global incidence, recurrence rate, and disability. Despite the limited availability of clinical therapies for IS, further research is essential to develop traditional Chinese medicine (TCM)-based neuroprotective treatments. This study aims to investigate the neuroprotective properties of mirificin against neuronal damage and uncover the pharmacological mechanisms involved. Mirificin levels in rat cerebrospinal fluid (CSF) and plasma following oral administration of Naomaitong (NMT) were analyzed using ultra high-performance liquid chromatography-mass spectrometry (UHPLC-MS). Middle cserebral artery occlusion (MCAO) models were utilized to assess the effects of mirificin, with cerebral infarction size determined using TTC staining and neurobehavioral evaluation. Oxygen-glucose deprivation/reperfusion (OGD/R) experiments were conducted on PC12 cells to evaluate cell viability through CCK-8 and LDH assays. The predictive analysis of mirificin's potential therapeutic targets and pharmacological mechanisms was conducted employing advanced computational strategies such as Network Pharmacology (NP) and molecular docking simulations, which were further verified by corresponding antagonists. Mirificin was present in drug-containing plasma and CSF. Mirificin reduced infarct size, improved neurological function in vivo, and exerted dose-dependent neuroprotective effects towards OGD/R-injured PC12 cells. Moreover, the core targets of mirificin were predicted to be VEGFR2, CAT, MMP9, and HSP1A1. Antagonists of VEGFR2 and HSP1A1 inhibited the neuroprotective effects of mirificin. The neuroprotective effect of mirificin against OGD/R-induced neuronal injury appears to be mediated, at least in part, by targeting VEGFR2 and HSP1A1.
Indexed as
Identifiers
41182350What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.